ReSTORE: Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

• Sponsor: Cidara Therapeutics Inc. (Industry)
• Overall Status: Completed
• CT.gov ID: NCT03667690
• Collaborator: (none)
• Enrollment: 199
• Locations: 132
• Arms: 2
• Actual Duration (Months): 36
• Patients Per Site: 1.5
• Patients Per Site Per Month: 0

Study Details

Study Description

Brief Summary

The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the treatment of candidemia and/or invasive candidiasis when compared to caspofungin (followed by optional oral fluconazole).

Condition or Disease	Intervention/Treatment	Phase
Candidemia; Mycoses; Fungal Infection; Invasive Candidiases	Drug: Rezafungin for Injection; Drug: Caspofungin; Drug: Fluconazole; Drug: intravenous placebo; Drug: oral placebo	Phase 3

Detailed Description

A Phase 3, multicenter, prospective, randomized, double-blind, efficacy and safety study of Rezafungin for Injection versus an active comparator regimen of caspofungin followed by optional oral fluconazole step-down therapy in subjects with candidemia and/or invasive candidiasis.

Study Design

• Study Type: Interventional
• Actual Enrollment: 199 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety of Rezafungin for Injection vs. Intravenous Caspofungin Followed by Oral Fluconazole Step Down in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis
• Actual Study Start Date: Oct 7, 2018
• Actual Primary Completion Date: Oct 7, 2021
• Actual Study Completion Date: Oct 7, 2021

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Group 1: Rezafungin for Injection Subjects in Rezafungin treatment group will receive a 400 mg loading dose in Week 1, followed by 200 mg once weekly, for a total of 2 to 4 doses. Daily intravenous placebo infusions, when not administered Rezafungin and a daily placebo for oral step-down therapy (first eligibility on Day 4 or later as advised by a site's national/regional/local guidelines) administered every day.	Drug: Rezafungin for Injection; Intravenous antifungal therapy; Drug: oral placebo; Microcrystalline cellulose; Other Names: encapsulated cellulose
Active Comparator: Group 2: Caspofungin Subjects in caspofungin arm will receive a total treatment of ≥14 days beginning with a single caspofungin 70 mg IV loading dose on Day 1 followed by 50 mg IV once daily up to 28 days. After ≥3 days of caspofungin treatment(or the minimum duration of IV therapy advised by the site's national/regional/local guidelines, whichever is greater), subjects may be switched to oral fluconazole if specific parameters are met. If the subject qualifies, then oral step-down therapy of fluconazole (6 mg/kg to the nearest 200 mg) is administered. After switch to oral step down before Day 8, subjects in the caspofungin group will receive IV placebo on Day 8 to preserve the study blind.	Drug: Caspofungin; Intravenous antifungal therapy; Other Names: Cancidas ; Drug: Fluconazole; Oral antifungal therapy; Other Names: generic fluconazole ; Drug: intravenous placebo; Normal saline; Other Names: placebo infusion

Outcome Measures

Primary Outcome Measures

1. All cause mortality (US FDA only) [Day 30 (-2 days)]

   The number of subjects in each treatment group who are alive and deceased (or with missing data) in the mITT population.

2. All cause mortality (US FDA only) [Day 30 (-2 days)]

   The percentage of subjects in each treatment group who are alive and deceased (or with missing data) in the mITT population.

3. Global Cure (EU only) [Day 14 (±1 day)]

   The number of subjects in each treatment group who have a global response of cure (clinical cure as assessed by the Investigator, radiological cure [for qualifying invasive candidiasis subjects at baseline], and mycological eradication, as confirmed by the DRC), failure and indeterminate in the modified Intent to Treat (mITT2) population.

4. Global Cure (EU only) [Day 14 (±1 day)]

   The percentage of subjects in each treatment group who have a global response of cure (clinical cure as assessed by the Investigator, radiological cure [for qualifying invasive candidiasis subjects], and mycological eradication, as confirmed by the DRC), failure and indeterminate in the modified Intent to Treat (mITT) population.

Secondary Outcome Measures

1. Global Cure [Day 14 (±1 day)]

   The number of subjects in each treatment group who have a global response of cure (clinical cure as assessed by the Investigator, radiological cure [for qualifying invasive candidiasis subjects at baseline], and mycological eradication, as confirmed by the DRC), failure and indeterminate in the mITT population.

2. Global Cure [Day 5, Day 30 (-2 days), EOT (≤2 days of last dose) and Follow-up (Days 52-59)]

   The number of subjects in each treatment group who have a global response of cure (clinical cure as assessed by the Investigator, radiological cure [for qualifying invasive candidiasis subjects at baseline], and mycological eradication, as confirmed by the DRC), failure and indeterminate in the mITT population.

3. Global Cure [Day 14 (±1 day)]

   The percentage of subjects in each treatment group who have a global response of cure (clinical cure as assessed by the Investigator, radiological cure [for qualifying invasive candidiasis subjects at baseline], and mycological eradication, as confirmed by the DRC), failure and indeterminate in the mITT population.

4. Global Cure [Day 5, Day 30 (-2 days), EOT (≤2 days of last dose) and Follow-up (Days 52-59)]

   The percentage of subjects in each treatment group who have a global response of cure (clinical cure as assessed by the Investigator, radiological cure [for qualifying invasive candidiasis subjects at baseline], and mycological eradication, as confirmed by the DRC), failure and indeterminate in the mITT population.

5. All cause mortality (EU only) [Day 30 (-2 days)]

   The number of subjects in each treatment group who are alive and deceased (or with missing data) in the mITT population.

6. All cause mortality (EU only) [Day 30 (-2 days)]

   The percentage of subjects in each treatment group who are alive and deceased (or with missing data) in the mITT population.

7. Comparison of Global Response (as confirmed by the DRC) [Day 5, Day 30 (-2 days), End Of Treatment (≤2 days of last dose) and Follow-up (Days 52-59).]

   The number of subjects with a global response of cure, failure, or indeterminate will be presented by treatment group in the mITT population

8. Comparison of Global Response (as confirmed by the DRC) [Day 5, Day 30 (-2 days), End Of Treatment (≤2 days of last dose) and Follow-up (Days 52-59).]

   The percentage of subjects with a global response of cure, failure, or indeterminate will be presented by treatment group in the mITT population

9. Comparison of Mycological Response [Day 5, Day 14 (±1 day), Day 30 (-2 days), End Of Treatment (≤2 days of last dose), and Follow-up (Days 52-59).]

   The number of subjects with a mycological response of eradication, failure, or indeterminate, by treatment group, in the mITT population

10. Comparison of Mycological Response [Day 5, Day 14 (±1 day), Day 30 (-2 days), End Of Treatment (≤2 days of last dose), and Follow-up (Days 52-59).]

    The percentage of subjects with a mycological response of eradication, failure, or indeterminate, by treatment group, in the mITT population

11. Comparison of Clinical Cure [Day 5, Day 14 (±1 day), Day 30 (-2 days), End Of Treatment (≤2 days of last dose), and Follow-up (Days 52-59).]

    The number of subjects with a clinical response of cure, failure, or indeterminate, presented by treatment group, in the mITT population

12. Comparison of Clinical Cure [Day 5, Day 14 (±1 day), Day 30 (-2 days), End Of Treatment (≤2 days of last dose), and Follow-up (Days 52-59).]

    The percentage of subjects with a clinical response of cure, failure, or indeterminate, presented by treatment group, in the mITT population

13. Incidence of treatment emergent adverse events [Safety and Tolerability] [Day 1 through Follow-up visit (Days 52-59)]

    Number of Subjects with Incidence of Treatment Emergent Adverse Events based on clinical chemistry, hematology and urine analysis laboratory test, vital sign, physical exams and ECG abnormalities.

14. Evaluate Pharmacokinetics (Cmax) [Day 1; Days 2, 3, 4, or 5 (one sample on one day only); Day 8; Day 14 (for subjects not receiving a Day 15 dose); Day 15 (if applicable) and Day 22 (if applicable)]

    Evaluate maximum plasma concentration (Cmax)

15. Evaluate Pharmacokinetics (Time to Cmax [Tmax]) [Day 1; Days 2, 3, 4, or 5 (one sample on one day only); Day 8; Day 14 (for subjects not receiving a Day 15 dose); Day 15 (if applicable) and Day 22 (if applicable)]

    Evaluate Tmax (time to Cmax)

16. Evaluate Pharmacokinetics (AUC) [Day 1; Days 2, 3, 4, or 5 (one sample on one day only); Day 8; Day 14 (for subjects not receiving a Day 15 dose); Day 15 (if applicable) and Day 22 (if applicable)]

    Evaluate area under the curve (AUC)

17. Comparison of Radiological Cure [Day 5, Day 14 (±1 day), Day 30 (-2 days), EOT (≤2 days of last dose), and Follow-up (Days 52-59)]

    The number of invasive candidiasis subjects with radiological cure, failure, or indeterminate, presented by treatment group, in the mITT population.

18. Comparison of Radiological Cure [Day 5, Day 14 (±1 day), Day 30 (-2 days), EOT (≤2 days of last dose), and Follow-up (Days 52-59)]

    The percentage of invasive candidiasis subjects with radiological cure, failure, or indeterminate, presented by treatment group, in the mITT population.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Willing and able to provide written informed consent. If the subject is unable to consent for himself/herself, a legally acceptable representative must provide informed consent on his/her behalf.

2. Males or females ≥18 years of age.

3. Established mycological diagnosis of candidemia and/or invasive candidiasis from a sample taken ≤4 days (96 hours) before randomization defined as

• ≥1 blood culture positive for yeast or Candida OR

• Positive test for Candida from a Sponsor-approved rapid IVD OR

• Positive gram stain (or other method of direct microscopy) for yeast or positive culture for Candida spp. from a specimen obtained from a normally sterile site.

1. Presence of one or more systemic signs attributable to candidemia or invasive candidiasis appearing from ≤12 hours prior to the qualifying positive culture through time of randomization.

2. Willing to initiate or continue medical treatment to cure infections, including receipt of antibiotics and surgical procedures, if required.

3. Female subjects of childbearing potential (all female subjects between 18 years <2 years post-menopausal unless surgically sterile) must agree to and comply with using one barrier method (e.g., female condom with spermicide) plus one other highly effective method of birth control, or sexual abstinence while participating in this study. Male subjects must be vasectomized, abstain from sexual intercourse, or agree to use barrier contraception, and also agree not to donate sperm while participating in the study and for 90 days thereafter (and at least 120 days from the last dose of study drug).

4. For Candidemia only subjects, drawing of a set of blood cultures within 12 hours prior to randomization in the study. The result of these blood cultures is not required for inclusion in the study.

Exclusion Criteria:

1. Any of the following forms of invasive candidiasis at baseline:

2. Septic arthritis in a prosthetic joint (septic arthritis in a native joint is allowed)

3. Osteomyelitis

4. Endocarditis or myocarditis

5. Meningitis, endophthalmitis, chorioretinitis, or any central nervous system infection

6. Chronic disseminated candidiasis

7. Urinary tract candidiasis due to ascending Candida infection secondary to obstruction or surgical instrumentation of the urinary tract

8. Received systemic treatment with an antifungal agent at approved doses for treatment of candidemia for >48 hours (e.g., >2 doses of a once daily antifungal agent or >4 doses of a twice daily antifungal agent) ≤4 days (96 hours) before randomization

1. Exception: Receipt of antifungal therapy to which any Candida spp. isolated in culture is not susceptible

1. Alanine aminotransferase or aspartate aminotransferase levels >10-fold the upper limit of normal

2. Severe hepatic impairment in subjects with a history of chronic cirrhosis (Child-Pugh score >9)

3. Presence of an indwelling vascular catheter or device that cannot be removed or an abscess that cannot be drained and is likely to be the source of candidemia or invasive candidiasis

4. Known hypersensitivity to Rezafungin for Injection, caspofungin, any echinocandin, or to any of their excipients

5. Meets National Cancer Institute Common Terminology Criteria for Adverse Events, version 5, criteria for ataxia, tremor, motor neuropathy, or sensory neuropathy of Grade 2 or higher

6. History of severe ataxia, tremor, or neuropathy or a diagnosis of multiple sclerosis or a movement disorder (including Parkinson's Disease or Huntington's Disease)

7. Planned or ongoing therapy at Screening with a known neurotoxic medication

8. Previous participation in this or any previous rezafungin study

9. Current participation in another interventional treatment trial with an investigational agent

10. Recent use of an investigational medicinal product within 28 days of the first dose of study drug or presence of an investigational device at the time of screening.

11. Pregnant or lactating females

12. The Principal Investigator (PI) is of the opinion the subject should not participate in the study

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	University of Alabama	Birmingham	Alabama	United States	35294
2	UC Davis	Sacramento	California	United States	95817
3	Emory University Hospital	Atlanta	Georgia	United States	30322
4	Augusta University	Augusta	Georgia	United States	30912
5	Johns Hopkins	Baltimore	Maryland	United States	21287
6	Henry Ford Health System	Detroit	Michigan	United States	48202
7	University of Minnesota	Minneapolis	Minnesota	United States	55455
8	Mayo Clinic Hospital-Rochester	Rochester	Minnesota	United States	55902
9	University of Mississippi Medical Center	Jackson	Mississippi	United States	39216
10	Washington University St. Louis	Saint Louis	Missouri	United States	63110
11	Mecury Street Medical	Butte	Montana	United States	59701
12	University of North Carolina	Chapel Hill	North Carolina	United States	27514
13	Duke University Medical Center	Durham	North Carolina	United States	27710
14	ID Clinical Research, Ltd.	Toledo	Ohio	United States	43608
15	University of Pittsburgh Falk Medical Center	Pittsburgh	Pennsylvania	United States	15213
16	Reading Hospital and Medical Center	West Reading	Pennsylvania	United States	19611
17	The University of Texas Health Science Center at San Antonio	San Antonio	Texas	United States	78229
18	Baylor Scott and White Medical Center	Temple	Texas	United States	76508
19	Carilion Clinic	Roanoke	Virginia	United States	24014
20	Alexander Fleming Specialized Medical Institute	Buenos Aires		Argentina
21	Cordoba Private Hospital	Córdoba		Argentina	5016
22	Allende Sanatorium	Córdoba		Argentina
23	Mayo Private Sanatorium	Córdoba		Argentina
24	Italian Hospital of Mendoza	Mendoza		Argentina
25	Westmead Public Hospital	Northmead	New South Wales	Australia	2152
26	Monash Health	Clayton	Victoria	Australia	3168
27	Peter MacCallum Cancer Centre	Melbourne	Victoria	Australia	3000
28	Alfred Health	Melbourne	Victoria	Australia	3004
29	Royal Melbourne Hospital (RMH)	Parkville	Victoria	Australia	3052
30	Brugmann University Hospital Center	Brussels		Belgium	1020
31	Erasme Hospital	Brussels		Belgium	1070
32	University Hospital Brussels	Brussels		Belgium	1090
33	Saint Luc University Hospital	Brussels		Belgium	1200
34	University Hospitals Leuven, Campus Gasthuisberg	Leuven		Belgium	3000
35	Multiprofile Hospital for Active Treatment Puls	Blagoevgrad		Bulgaria	2700
36	University Multiprofile Hospital for Active Treatment and Emergency Medicine N.I. Pirogov EAD, Sofia, Clinic of Purulent-Septic Surgery	Sofia		Bulgaria	1606
37	University Multiprofile Hospital for Active Treatment and Emergency Medicine N.I. Pirogov EAD	Sofia		Bulgaria	1606
38	The First Affiliated Hospital of Bengbu Medical College	Bengbu	Anhui	China	233004
39	The Second People's Hospital of Hefei	Hefei	Anhui	China	230011
40	The Second Hospital of Anhui Medical University	Hefei	Anhui	China	230601
41	Chongqing People's Hospital	Chongqing	Chongqing	China	400013
42	Guangzhou First People's Hospital	Guangzhou	Guangdong	China	510000
43	Guangdong Provincial People's Hospital	Guangzhou	Guangdong	China	510080
44	The First Affiliated Hospital of Guangzhou Medical University	Guangzhou	Guangdong	China	510120
45	Qingyuan People's Hospital	Qingyuan	Guangdong	China	511500
46	Zhongnan Hospital of Wuhan University	Wuhan	Hubei	China	430071
47	The Second Xiangya Hospital of Central South University	Changsha	Hunan	China	410008
48	Nanjing First Hospital	Nanjing	Jiangsu	China	210000
49	Zibo Central Hospital	Zibo	Shandong	China	255036
50	West China Hospital, Sichuan University	Chengdu	Sichuan	China	610065
51	Huashan Hospital Affiliated Fudan University	Shanghai		China	200040
52	Shanghai Pulmonary Hospital	Shanghai		China	200433
53	Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences	Tianjin		China	300020
54	General Hospital of Tianjin Medical University	Tianjin		China	300052
55	CEQUIN Foundation Cardiomet	Armenia		Colombia	630002
56	De La Costa Clinic Ltd.	Barranquilla		Colombia	080020
57	University IPS - Leon XIII Clinic	Medellín		Colombia	050012
58	Amiens Picardie University Hospital - South	Amiens		France	80480
59	Centre Hospitalier Victor Dupouy - Argenteuil	Argenteuil		France	95107
60	Roger Salengro Hospital	Lille		France	59037
61	Marseille University Hospital Center - North Hospital	Marseille		France	13015
62	Hotel Dieu Hospital Nantes University Hospital Center	Nantes		France	44093
63	Saint-Louis Hospital	Paris		France	75475
64	Paris University Hospitals Center - Cochin Hospital	Paris		France	95107
65	University Hospital Center of Poitiers	Poitiers		France	86021
66	Civil Hospital of Strasbourg	Strasbourg		France	67091
67	Tours University Hospital Center, Bretonneau Hospital	Tours		France	37000
68	University Hospital Köln	Cologne		Germany	50937
69	University Hospital Freiburg	Freiburg		Germany	79106
70	Johannes Gutenberg University Medical Center	Mainz		Germany	55131
71	General Hospital of Athens "Evangelismos", 5th Department of Internal Medicine and Infectious Diseases Unit	Athens		Greece	10676
72	General Hospital of Athens "Evangelismos"	Athens		Greece	10676
73	General Hospital of Athens "Laikon", Infectious Diseases Unit	Athens		Greece	11527
74	General Hospital of Athens "Laikon"	Athens		Greece	11527
75	General Hospital of Thessaloniki Ippokratio	Thessaloníki		Greece	54642
76	Bnai Zion Medical Center	Haifa		Israel	3339419
77	Lady Davis Carmel Medical Center	Haifa		Israel	3436212
78	Rambam Health Care Campus	Haifa		Israel	35254
79	Edith Wolfson Medical Center	H̱olon		Israel	5822012
80	Hadassah Medical Center	Jerusalem		Israel	9112001
81	The Baruch Padeh Medical Center	Nazareth		Israel	16100
82	Ziv Medical Center	Safed		Israel	1311001
83	The Tel Aviv Sourasky Medical Center	Tel Aviv		Israel	6423906
84	Chaim Sheba Medical Center	Tel Hashomer		Israel	5262000
85	Polyclinic S. Orsola-Malpighi, Dept. of Organ Impairment and Transplants	Bologna		Italy	40138
86	ASST Large Metropolitan Hospital Niguarda, Infectious Diseases Department	Milan		Italy	20161
87	University Polyclinic Hospital of Modena	Modena		Italy	41124
88	University Hospital of Modena	Modena		Italy	71-41124
89	University of Milano-Bicocca - San Gerardo Hospital	Monza		Italy	20900
90	University Polyclinic Hospital "Paolo Giaccone" Palermo, Infectious Disease Department, ICU	Palermo		Italy	90127
91	University Polyclinic Foundation Agostino Gemelli - IRCCS	Rome		Italy	00168
92	Integrated University Health Authority of Trieste	Trieste		Italy	34125
93	Integrated University Hospital "Santa Maria della Misericordia" of Udine	Udine		Italy	22100
94	Wonju Severance Christian Hospital	Wŏnju	Gangwon-do	Korea, Republic of	26426
95	Dong-A University Hospital	Busan		Korea, Republic of	49201
96	Severance Hospital, Yonsei University Health System	Seoul		Korea, Republic of	03722
97	Samsung Medical Center	Seoul		Korea, Republic of	06351
98	Chung-Ang University Hospital	Seoul		Korea, Republic of	06793
99	Ajou University Hospital	Suwon		Korea, Republic of	16499
100	National University Hospital	Singapore		Singapore	119074
101	Tan Tock Seng Hospital	Singapore		Singapore	119074
102	University Hospital Germans Trias i Pujol	Badalona		Spain	08916
103	University Hospital Cruces	Baracaldo		Spain	48903
104	Hospital del Mar, Department of Infectious Diseases	Barcelona		Spain	08003
105	University Hospital Vall d'Hebron (HUVH)	Barcelona		Spain	08035
106	Hospital Clinic of Barcelona	Barcelona		Spain	08036
107	Parc Tauli Health Corporation	Barcelona		Spain	08208
108	General University Hospital Gregorio Maranon	Madrid		Spain	28007
109	University Hospital Ramon y Cajal	Madrid		Spain	28034
110	University Hospital Clinical San Carlos	Madrid		Spain	28040
111	La Paz University Hospital	Madrid		Spain	28046
112	University Hospital Puerta de Hierro Majadahonda	Majadahonda		Spain	28220
113	University Hospital Virgen Macarena	Sevilla		Spain	41009
114	University and Polytechnic Hospital La Fe	Valencia		Spain	46026
115	Kaohsiung Medical University Chung-Ho Memorial Hospital	Kaohsiung		Taiwan	80756
116	China Medical University Hospital	Taichung		Taiwan	40447
117	National Taiwan University Hospital	Taipei		Taiwan	10002
118	Taipei Veterans General Hospital	Taipei		Taiwan	11217
119	Linkou Chang Gung Memorial Hospital	Taoyuan City		Taiwan	333
120	King Chulalongkorn Memorial Hospital	Bangkok		Thailand	10330
121	Rajavithi Hospital	Bangkok		Thailand	10400
122	Ramathibodi Hospital	Bangkok		Thailand	10400
123	Siriraj Hospital	Bangkok		Thailand	10700
124	Maharaj Nakorn Chiang Mai Hospital	Chiang Mai		Thailand	50200
125	Srinagarind Hospital	Khon Kaen		Thailand	40002
126	Thammasat University Hospital	Pathum Thani		Thailand	12120
127	Songklanagarind Hospital	Songkhla		Thailand	90110
128	Hacettepe University School of Medicine	Ankara		Turkey	06100
129	Ankara University School of Medicine	Ankara		Turkey	06230
130	Istanbul University School of Medicine	Istanbul		Turkey	34093
131	Marmara University Pendik Training and Research Hospital	Istanbul		Turkey	34899
132	Medipol Mega University Hospital	Istanbul		Turkey

Sponsors and Collaborators

• Cidara Therapeutics Inc.

Investigators

• Study Director: Taylor Sandison, MD, MPH, Cidara Therapeutics Inc.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Cidara Therapeutics Inc.
• ClinicalTrials.gov Identifier: NCT03667690
• Other Study ID Numbers: CD101.IV.3.05
• First Posted: Sep 12, 2018
• Last Update Posted: Feb 8, 2022
• Last Verified: Feb 1, 2022

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No
• Keywords provided by Cidara Therapeutics Inc.: Mycoses; Candidiasis; Candidiasis, Invasive; Candidemia; Fungemia; Sepsis; Invasive Fungal Infections; Systemic Inflammatory Response Syndrome; Pathologic Processes; Fluconazole; Caspofungin; Echinocandins; Antifungal Agents; Anti-infective Agents; 14-alpha Demethylase Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Steroid Synthesis Inhibitors; Physiological Effects of Drugs; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors
• Additional relevant MeSH terms: Mycoses; Candidiasis; Candidemia; Candidiasis, Invasive; Fluconazole; Caspofungin; Rezafungin

Study Results

No Results Posted as of Feb 8, 2022